NOS1 and diabetes mellitus: Furthermore, emerging pharmacological agents designed to enhance nNOS activity or mimic its effects selectively may represent a new avenue for DKD therapy, potentially restoring renal hemodynamics and counteracting diabetes-induced renal damage [79,80].